Concizumab

Concizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetTissue factor pathway inhibitor
Clinical data
Trade namesAlhemo
Pregnancy
category
Routes of
administration		Subcutaneous
Drug classAntihemorrhagic
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
UNII
KEGG
Chemical and physical data
FormulaC6462H10004N1712O2046S46
Molar mass145887.81 g·mol−1

Concizumab, sold under the brand name Alhemo, is a monoclonal antibody used for the treatment of hemophilia B.[5] It is an anti-tissue factor pathway inhibitor.[5]

Concizumab was approved for medical use in Canada in March 2023.[4][7]

  1. ^ a b "Alhemo APMDS". Therapeutic Goods Administration (TGA). 29 September 2023. Archived from the original on 10 March 2024. Retrieved 7 March 2024.
  2. ^ "Alhemo (Novo Nordisk Pharmaceuticals Pty Ltd)". Therapeutic Goods Administration (TGA). 28 July 2023. Archived from the original on 10 March 2024. Retrieved 10 September 2023.
  3. ^ "AusPAR: Alhemo". Therapeutic Goods Administration (TGA). 18 March 2024. Retrieved 31 March 2024.
  4. ^ a b "Alhemo Product information". Health Canada. 10 March 2023. Archived from the original on 24 March 2023. Retrieved 9 June 2023.
  5. ^ a b c "Alhemo (concizumab injection) Product Monograph" (PDF). Health Canada. Archived (PDF) from the original on 3 March 2024. Retrieved 3 March 2024.
  6. ^ "Summary Basis of Decision for Alhemo". Health Canada. 31 May 2023. Archived from the original on 10 March 2024. Retrieved 9 June 2023.
  7. ^ "Health Canada approves Alhemo, the first subcutaneous prophylactic treatment for people living with hemophilia B with inhibitors" (Press release). Novo Nordisk Canada. 17 April 2023. Archived from the original on 9 June 2023. Retrieved 9 June 2023 – via Newswire.